UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

1-LB: Advancing Therapy in Basal Insulin Users with Type 2 Diabetes (T2D): Hypoglycemia as a Function of HbA1c in the SoliMix Trial

Diabetes (New York, N.Y.), 2021-06, Vol.70 (Supplement_1)

2021

Volltextzugriff (PDF)

1090-P: Reaching ADA Glycemic Targets without Hypoglycemia during Titration with Gla-300 and IDeg in T2DM: Exploratory Analyses from BRIGHT

Diabetes (New York, N.Y.), 2019-06, Vol.68 (Supplement_1)

2019

Volltextzugriff (PDF)

1241-P: Cross-Sectional Study of the Impact of the COVID-Pandemic on Diabetes Management in Primary Care in Ontario, Canada

Diabetes (New York, N.Y.), 2022-06, Vol.71 (Supplement_1)

2022

Volltextzugriff (PDF)

131-LB: Differences in HbA1c Reduction between Insulin Glargine 300 U/mL (Gla-300) and Insulin Degludec 100 U/mL (IDeg-100) in Adults ≥70 Years of Age with T2DM in the BRIGHT Trial

Diabetes (New York, N.Y.), 2019-06, Vol.68 (Supplement_1)

2019

Volltextzugriff (PDF)

2022 Canadian Cardiovascular Society Guideline for Use of GLP-1 Receptor Agonists and SGLT2 Inhibitors for Cardiorenal Risk Reduction in Adults

Canadian journal of cardiology, 2022-08, Vol.38 (8), p.1153-1167

2022

Volltextzugriff (PDF)

206 - Efficacy of tirzepatide in achieving the composite endpoints of glycemic, blood pressure and lipid goals in SURMOUNT-2

Obesity research & clinical practice, 2024-09, Vol.18 (5), p.34-35

2024

Volltextzugriff (PDF)

260-OR: iGlarLixi vs. Basal plus Rapid-Acting Insulin in Adults with Type 2 Diabetes Advancing from Basal Insulin Therapy: The SoliSimplify Real-World Study

Diabetes (New York, N.Y.), 2022-06, Vol.71 (Supplement_1)

2022

Volltextzugriff (PDF)

268-OR: Impact of the COVID-Pandemic on Antihyperglycemic Prescription Patterns in Canada

Diabetes (New York, N.Y.), 2022-06, Vol.71 (Supplement_1)

2022

Volltextzugriff (PDF)

49 - The Importance of Timely Pharmacological Adjustment in People with T2D: Key Learnings From a 2015 Canadian Personal Practice Assessment

Canadian journal of diabetes, 2017-10, Vol.41 (5), p.S18-S18

2017

Volltextzugriff (PDF)

668-P: Body Weight Loss with Oral Semaglutide Is Predominantly Mediated by Effects Other than Gastrointestinal Adverse Events

Diabetes (New York, N.Y.), 2021-06, Vol.70 (Supplement_1)

2021

Volltextzugriff (PDF)

718-P: Patients Achieving an HbA1c <5.7% with =5% Weight Loss and without Hypoglycemia: A Post Hoc Analysis of SURPASS 1 to 5

Diabetes (New York, N.Y.), 2022-06, Vol.71 (Supplement_1)

2022

Volltextzugriff (PDF)

748-P: Advancing Therapy in Uncontrolled Basal Insulin (BI)-Treated Type 2 Diabetes (T2D): Subanalysis of the SoliMix Trial in Participants in Europe

Diabetes (New York, N.Y.), 2021-06, Vol.70 (Supplement_1)

2021

Volltextzugriff (PDF)

749-P: Advancing Therapy in Uncontrolled Basal Insulin (BI)-Treated Type 2 Diabetes (T2D): Subanalysis of the SoliMix Trial Outside Europe

Diabetes (New York, N.Y.), 2021-06, Vol.70 (Supplement_1)

2021

Volltextzugriff (PDF)

788-P: Predictors of Achieving Target HbA1c <7% in People with Type 2 Diabetes Advancing Treatment with iGlarLixi

Diabetes (New York, N.Y.), 2023-06, Vol.72 (Supplement_1), p.1

2023

Volltextzugriff (PDF)

800-P: Predictors of HbA1c and dTIR Responses with iGlarLixi in Type 2 Diabetes—Patient-Level Exploratory Analyses of the LixiLan-L Trial

Diabetes (New York, N.Y.), 2023-06, Vol.72 (Supplement_1), p.1

2023

Volltextzugriff (PDF)

Aberrant cholesterol metabolic signaling impairs antitumor immunosurveillance through natural killer T cell dysfunction in obese liver

Cellular & molecular immunology, 2022-07, Vol.19 (7), p.834-847

2022

Volltextzugriff (PDF)

Abstract A012: Mre11 mediates cGAS activation and tumor suppression through ZBP1-dependent necroptosis in breast cancer

Cancer research (Chicago, Ill.), 2024-01, Vol.84 (1_Supplement), p.A012-A012

2024

Volltextzugriff (PDF)

Accelerated Evolution of the Pituitary Adenylate Cyclase-Activating Polypeptide Precursor Gene During Human Origin

Genetics (Austin), 2005-06, Vol.170 (2), p.801-806

2005

Volltextzugriff (PDF)

ACCORD microvascular and Eye substudy: should the results change our practice?

Diabetes management (London), 2011-07, Vol.1 (4), p.389-396

2011

Volltextzugriff (PDF)

Achievement of glycaemic targets with weight loss and without hypoglycaemia in type 2 diabetes with the once‐weekly glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 receptor agonist tirzepatide: A post hoc analysis of the SURPASS‐1 to ‐5 studies

Diabetes, obesity & metabolism, 2023-04, Vol.25 (4), p.965-974

2023

Volltextzugriff (PDF)

Achieving Glycemic Control in Special Populations in Hospital: Perspectives in Practice

Canadian journal of diabetes, 2014-04, Vol.38 (2), p.134-138

Cheng, Alice Y.Y., MD, FRCPC

2014

Volltextzugriff (PDF)

Alienation, despair and hope as predictors of health, coping and nonengagement among nonengaged youth: manifestations of spiritual emptiness

Asia pacific journal of counselling and psychotherapy, 2013-03, Vol.4 (1), p.18-30

2013

Volltextzugriff (PDF)

Anti-neuroinflammatory effects of the calcium channel blocker nicardipine on microglial cells: implications for neuroprotection

PloS one, 2014-03, Vol.9 (3), p.e91167

2014

Volltextzugriff (PDF)

Antihelium-3 fluxes near Earth using data-driven estimates for annihilation cross section

37th International Cosmic Ray Conference,Berlin, Germany,2021-07-12 - 2021-07-23, 2022, Vol.395

2022

Volltextzugriff (PDF)

Application of the Characteristic Function in Financial Research

Handbook of Quantitative Finance and Risk Management, p.575-581

Volltextzugriff (PDF)

1 – 25 von 336

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(293)
Mit Volltextzugriff
(300)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(190)
Life Sciences & Biomedicine
(159)
Humans
(129)
Experiment
(64)
Particle Physics
(64)
Physics
(62)
High Energy Physics - Experiment
(60)
Male
(60)
Female
(58)
Diabetes
(50)
Endocrinology & Metabolism
(49)
Hep
(48)
Physics Of Elementary Particles And Fields
(48)
Adult
(38)
Hadron-Hadron Scattering
(37)
Middle Aged
(31)
Diabetes Mellitus
(29)
Risk Factors
(26)
Animals
(25)
Diabetes Mellitus, Type 2 - Drug Therapy
(25)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

1-LB: Advancing Therapy in Basal Insulin Users with Type 2 Diabetes (T2D): Hypoglycemia as a Function of HbA1c in the SoliMix Trial

1090-P: Reaching ADA Glycemic Targets without Hypoglycemia during Titration with Gla-300 and IDeg in T2DM: Exploratory Analyses from BRIGHT

1241-P: Cross-Sectional Study of the Impact of the COVID-Pandemic on Diabetes Management in Primary Care in Ontario, Canada

131-LB: Differences in HbA1c Reduction between Insulin Glargine 300 U/mL (Gla-300) and Insulin Degludec 100 U/mL (IDeg-100) in Adults ≥70 Years of Age with T2DM in the BRIGHT Trial

2022 Canadian Cardiovascular Society Guideline for Use of GLP-1 Receptor Agonists and SGLT2 Inhibitors for Cardiorenal Risk Reduction in Adults

206 - Efficacy of tirzepatide in achieving the composite endpoints of glycemic, blood pressure and lipid goals in SURMOUNT-2

260-OR: iGlarLixi vs. Basal plus Rapid-Acting Insulin in Adults with Type 2 Diabetes Advancing from Basal Insulin Therapy: The SoliSimplify Real-World Study

268-OR: Impact of the COVID-Pandemic on Antihyperglycemic Prescription Patterns in Canada

49 - The Importance of Timely Pharmacological Adjustment in People with T2D: Key Learnings From a 2015 Canadian Personal Practice Assessment

668-P: Body Weight Loss with Oral Semaglutide Is Predominantly Mediated by Effects Other than Gastrointestinal Adverse Events

718-P: Patients Achieving an HbA1c <5.7% with =5% Weight Loss and without Hypoglycemia: A Post Hoc Analysis of SURPASS 1 to 5

748-P: Advancing Therapy in Uncontrolled Basal Insulin (BI)-Treated Type 2 Diabetes (T2D): Subanalysis of the SoliMix Trial in Participants in Europe

749-P: Advancing Therapy in Uncontrolled Basal Insulin (BI)-Treated Type 2 Diabetes (T2D): Subanalysis of the SoliMix Trial Outside Europe

788-P: Predictors of Achieving Target HbA1c <7% in People with Type 2 Diabetes Advancing Treatment with iGlarLixi

800-P: Predictors of HbA1c and dTIR Responses with iGlarLixi in Type 2 Diabetes—Patient-Level Exploratory Analyses of the LixiLan-L Trial

Aberrant cholesterol metabolic signaling impairs antitumor immunosurveillance through natural killer T cell dysfunction in obese liver

Abstract A012: Mre11 mediates cGAS activation and tumor suppression through ZBP1-dependent necroptosis in breast cancer

Accelerated Evolution of the Pituitary Adenylate Cyclase-Activating Polypeptide Precursor Gene During Human Origin

ACCORD microvascular and Eye substudy: should the results change our practice?

Achievement of glycaemic targets with weight loss and without hypoglycaemia in type 2 diabetes with the once‐weekly glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 receptor agonist tirzepatide: A post hoc analysis of the SURPASS‐1 to ‐5 studies

Achieving Glycemic Control in Special Populations in Hospital: Perspectives in Practice

Alienation, despair and hope as predictors of health, coping and nonengagement among nonengaged youth: manifestations of spiritual emptiness

Anti-neuroinflammatory effects of the calcium channel blocker nicardipine on microglial cells: implications for neuroprotection

Antihelium-3 fluxes near Earth using data-driven estimates for annihilation cross section

Application of the Characteristic Function in Financial Research

Suchergebnisse filtern